Masella_Robert_WEB

Recently Featured

Paul, Weiss Adds Leading M&A Partner in New York

Mergers & Acquisitions

November 16, 2026

Robert F.
Masella

New York

1345 Avenue of the Americas
New York, NY 10105-0302

Practices & Industries

Mergers & Acquisitions

Corporate

Education

J.D., University of Pennsylvania Law School, magna cum laude

M.B.A., Wharton School, University of Pennsylvania, with distinction

Bar Admissions

New York

Rob Masella is a partner in the firm’s Mergers & Acquisitions Group. He has decades of experience advising public and private companies, corporate boards, private equity funds and financial institutions on complex domestic and cross-border M&A transactions across sectors. His practice includes advising on public and private M&A, dual-track M&A/IPO processes, joint ventures, option agreements, licensing and collaboration agreements and spin-offs. His broad experience spans many industries with a particular emphasis on life sciences. Rob also advises boards of directors on corporate governance, shareholder activism, fiduciary duties and conflict-of-interest matters.

Rob’s experience includes advising:

  • Color Wow in its sale to L’Oréal
  • SpringWorksin its merger with Merck KGaA
  • Ally Bridge in numerous investments
  • 2seventy bio in its merger with BMS
  • Teleflexin its acquisition of Biotronik's cardiovascular business
  • Ironshore Therapeutics in its sale to Collegium
  • Proteologixin its sale to Johnson & Johnson
  • Thomson Reuters in multiple transactions, including its acquisitionsof Materia, Noetica,Additive AI, REDI Technologies and Capital Confirmation and the sale of Gardiner-Caldwell, Physicians World, Physicians’ Desk Reference and Scientific Connexions
  • Pathos AI in its acquisition of Rain Oncology
  • AVROBIO in its merger with Tectonic
  • Acinoin its acquisition of M8 Pharmaceuticals
  • VersanisBio in its sale to Eli Lilly
  • Checkmate Pharmaceuticals in its merger with Regeneron
  • AvroBioin its gene therapy sale to Novartis
  • Intapp in its acquisitionsof Paragon Data Labs, OnePlace, DealCloudandRepstorLimitedand in its IPO
  • TCR2 in its merger with Adaptimmune
  • Henry Schein in its partnership with Rimidi
  • Caris Life Sciences in over $1 billion of growth equity financing
  • AcelRx in its acquisition of Lowell Therapeutics
  • OpenAI Foundation in numerous life science grants
  • MeiraGTx Holdings plc in its acquisition of Emrys Bio
  • Alnylam in various corporate governance matters
  • AcelRx in various corporate matters
  • Ultragenyx in its investment in Arcturus Therapeutics
  • Sonic Corp. in its sale to Inspire Brands
  • Knauf in its acquisition of USG Corporation for $7 billion
  • Knauf in its withhold campaign at USG Corporation
  • Retromer Pharma in multiple equity financings
  • Inspirna in various collaborations
  • MedeAnalytics in its acquisition of assets from The Advisory Board Company
  • MedeAnalytics, a portfolio company of Bain Capital, in its sale to Thoma Bravo
  • MedeAnalytics in its acquisition of OnFocus Healthcare
  • Shareholder of Interactive Data in its sale to the Intercontinental Exchange
  • Supreme Oil in its sale to Stratas Foods
  • Icopal in its sale to GAP
  • Mitsubishi in its $5.39 billion acquisition from Anglo American plc of a 24.5% interest in Anglo American Sur, a Chilean copper mining company
  • iParadigms, a portfolio company of Warburg Pincus, in its $752 million sale to Insight Venture Partners and GIC Special Situations
  • Milestone Apartments Real Estate Investment Trust, as US special counsel, in connection with its agreement to internalize its asset management business
  • Citibank in its sale of EMI Music to Universal Music Group and EMI Music Publishing to a consortium of investors
  • Bristol-Myers Squibb in its acquisition of DuPont Pharmaceuticals
  • Henry Schein in its investment in, and joint venture with, Maravet
  • Johnson & Johnson in its acquisition of Innovasive Devices
  • Oracle Corporation in its acquisition of Front Porch Digital
  • Hakkasan on its joint venture with MGM Resorts
  • Abertis Infraestructuras on the sale of Belfast International airport, Stockholm Skavsta airport, its Orlando airport terminal concession and its airport management business in the US
  • Platinum Equity on the acquisition of outdoor media assets from CBS Corporation
  • Riverside Partners on the acquisition of Bohemia Interactive Solutions
  • Quadriga Capital on the acquisition of Kinetic Systems
  • The special committee of Six Flags Entertainment in connection with the company's bankruptcy and assessment of competing plans of reorganization
  • iCrossing in the company's sale to the Hearst Corporation
  • Openwave in the sale of its mobile messaging and mediation businesses to Marlin Equity Partners
  • Lindsay Goldberg in its acquisition of First American Payment Systems
  • Ecolochem in its ultra clean water joint venture with Nalco and Ecolochem's sale to Ionics
  • The John Frieda Companies in their sale to Kao Corporation
  • Conoco in its merger with Phillips Petroleum
  • EchoStar in its spin-off from Dish Network
  • Global Signal in its merger with Crown Castle
  • Jones Apparel in its hostile acquisition of Maxwell Shoe
  • Media General in the sale of a number of television markets
  • Nestle in its merger with Ralston Purina
  • Financial Institutions in connection with numerous transactions, including, most recently, the sale of Silence Therapeutics to Merck KGaA; the sale of Soleno Therapeutics to Neurocrine; John Wiley’s acquisition of Emerald Publishing; the merger of ConocoPhillips and Marathon Oil; Envestnet’s sale to Bain Capital and Royalty Pharma’s acquisition of its manager

Rob serves on several advisory boards and professional committees. He has been a member of the Business Law Partner Advisory Board of Thomson Reuters Accelus, the National Advisory Committee of the Colonial Williamsburg Foundation, the New York Bar Association’s Committee on Mergers & Acquisitions and Corporate Control Contests, Law360’s Life Sciences Editorial Advisory Board and the New York Bar Association’s Corporation Law Committee. Rob sits on the board of LikeMinds Foundation, a not-for-profit that supports Alzheimer’s and Parkinson’s research, and on the board of TheChurch, a non-profit art center, exhibition space and artist residency.

Recently Featured

Paul, Weiss Adds Leading M&A Partner in New York

Mergers & Acquisitions

November 16, 2026